In pursuit of delivering patients the fastest possible visual restoration gene therapy
More than a million patients worldwide with inherited retinal disease are still waiting for an effective treatment that can end their fear of going blind.
Seeing them firsthand, a mission-driven ophthalmologist founded Restore Vision to develop a gene therapy to stop—even reverse—the disease in its tracks.
We can see a future where this too will be a treatable condition. And we want you to see it too.
Yusaku Katada, M.D., Ph.D.President & CEO
Hikaru MiyazakiExecutive Vice President & COO
Naoyuki Nakada, Ph.D.SVP, Preclinical Lead
Katsuyuki Nagai, Ph.D.CMC advisor
Shinichi Koizumi, Ph.D.Executive Advisor
Tsutomu Uchiyama, Ph.D.IP Strategy Advisor
Ken Shimokawa, Ph.D.Strategic Advisor
|Company Name||Restore Vision Inc.|
|Established||November 14, 2016|
|Representative||Yusaku Katada, M.D., Ph.D.|
|Business Activities||Research and development of regenerative medicine|